University of Miami Miller School of Medicine, USA
Talk Title: How Aging and Obesity Affect the Immune and Vaccine Responses
Bonnie Blomberg earned her BA in Biology and PhD in Immunology from the University of California, San Diego, then completed postdoctoral fellowships at the Basel Institute for Technology in Switzerland and Massachusetts Institute of Technology’s Center for Cancer Research before joining the faculty of the University of Miami in 1983. She is currently a Professor in the Department of Microbiology and Immunology.
View full bio
Dr. Blomberg’s area of expertise is cellular and molecular immunology, with a particular focus on B lymphocytes and aging. Her laboratory has developed molecular biomarkers for optimal B lymphocyte function, which decrease with age in mice and humans. These include the transcription factor E47, AID (activation induced cytidine deaminase), and IgG class switch recombination (CSR). Her lab found these to correlate with an optimal influenza vaccine immune response in humans and to be decreased in the elderly. They have also shown that inflammation systemically (serum) and in unstimulated B cells increases with age in mice and humans and negatively affects their function. Dr. Blomberg has recently extended studies to contributors to inflammation including obesity and mechanisms for antibody and B cell function generated therein.
Dr. Blomberg has been a frequent advisor to the World Health Organization on aging, the immune system, and vaccine response, received an NIH Merit Award in 2005, is a member of and active in the American Association of Immunologists (AAI), and the Federation of Clinical Immunology Societies (FOCIS), has served on numerous grant review boards, and serves on the editorial board of Aging Cell.
World Health Organization, Switzerland
Talk Title: Disease eradication in human populations: challenges and opportunities
View full bio
More information coming soon
Talk Title: Innovation in real-time surveillance for influenza burden and vaccine effectiveness
Alicia Fry earned her Doctorate of Medicine from the University of Cincinnati, College of Medicine in Ohio, and trained in Internal Medicine at Johns Hopkins Hospital in Baltimore and Infectious Diseases at University of California, San Francisco.
View full bio
She has a Master of Public Health from the University of California, Berkeley. She has worked in the Influenza Division, National Centers for Disease Control and Prevention at CDC since 2007 and is currently the chief of the Epidemiology and Prevention Branch. She has expertise in influenza antiviral agents and vaccines. Dr. Fry’s work is documented in over 200 peer-reviewed research articles, Morbidity and Mortality Weekly Reports, and book chapters.
Jose de la Fuente
SaBio. Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM-JCCM), Spain and Oklahoma State University, USA
Talk Title: Targeting host-vector-pathogen interactions to reduce the global burden of vector-borne diseases
José de la Fuente Graduated in Physics at Moscow State University and University of Havana in 1984. Ph.D. in Biology at University of Havana.
View full bio
Current position: Professor, SaBio, Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM), Spain and Adjunct Professor, Department of Veterinary Pathobiology. Center for Veterinary Health Sciences, Oklahoma State University, U.S.A. Head of the Genomics, Proteomics & Biotechnology Lab. Thirty-three years experience in research, education and as Principal Investigator in research projects. Over 600 published papers in international journals and 5 books in areas of basic molecular biology and biotechnology. Patents: 30. PhD thesis supervised: 32. Current Research Interests: Infectious diseases. Molecular biology of host-vector-pathogen interactions, gene regulation, pathogenesis, functional genomics, evolution and immunology. Systems biology. Ticks and tick-borne diseases. Intracellular bacteria (Rickettsia, Anaplasma, Mycobacterium). Vaccinology. Biotechnology.
Google scholar profile: http://scholar.google.com/citations?user=Cu4qOlgAAAAJ&hl.
ResearchGate profile: https://www.researchgate.net/profile/Jose_De_la_Fuente/?ev=hdr_xprf.
University of Tokyo, Japan
Talk Title: The nasal immune system for the vaccine development
Hiroshi Kiyono obtained his dental degree (D.D.S.) from Nihon University, and Ph.D. from the University of Alabama at Birmingham (UAB). His background as a dentist combined with extensive research experience in the field of Mucosal Immunology at UAB, Max-Planck Institute, Osaka University and at present, the University of Tokyo, Chiba University and University of California, San Diego makes him exceptionally well qualified to discuss the current and future directions of mucosal immunology and mucosal vaccine development.
View full bio
To reflect his scientific contribution, he was listed in ISI Highly Cited Researchers’ List and received several prestigious awards such as NIH New Investigator Research Award, NIH Research Career Development Award, The Japanese Society for Vaccinology Takahashi Award and Hideyo Noguchi Memorial Medical Science Award.
He was the former President of Society for Mucosal Immunology. He also contributed to scientific Journals such as Vaccine, Mucosal Immunology, Human Vaccines and Frontiers as the editorial board members. He himself has a total of 528 publications in peer review journals and edited a total of 20 books.
He served as the Dean of the Institute of Medical Science, The University of Tokyo and is currently Director and Project Professor for International Research and Development Center for Mucosal Vaccines, and Project Professor for Division of Mucosal Immunology, IMSUT Distinguished Professor Unit at the same institute. He is also holding an Adjunct Professorship at Chiba University in Japan. He has also initiated to establish new Mucosal Immunology, Allergy and Vaccine research program at the University of California, San Diego as a Professor.
University of Colorado Anschutz Medical Campus, USA
Talk Title: Recombinant Glycoprotein E Adjuvanted Herpes Zoster Vaccine
Myron Levin graduated from Harvard Medical School in 1960. He completed a residency in Internal Medicine at the Bronx Municipal hospital Center (Einstein Medical School), and spent the next three years at the National Institutes of Health; the last two years at NIH were devoted to research in molecular virology.
View full bio
Dr. Levin returned to Harvard in 1969 to complete a fellowship in Infectious Diseases with the combined adult-pediatric training program at the Children’s Hospital and the Beth Israel Hospital, and remained as the first Chief of Infectious Diseases at the Sidney Farber Cancer Center (now the Dana-Farber Cancer Institute).
From 1982 to 2000 he was Chief of Pediatric Infectious Diseases at the University of Colorado School of Medicine and the Children’s Hospital of Denver, and Director of the Clinical Virology Laboratory at the University of Colorado Hospital. He is a Professor of Pediatrics and Medicine. Dr. Levin directs a clinic for research on experimental vaccines and antiviral drugs, and maintains the HIV clinic for children and pregnant women at Children’s Hospital Colorado.
Dr. Levin’s clinical interests are in antiviral therapy, the immune response to herpesvirus infections, and vaccine science. His laboratory studies focus on latency of herpesviruses in human neurons, and the nature of latent herpesviruses in human ganglia. Clinical studies focus on the immune response to established and experimental vaccines and correlates of protection, especially in older vaccinees. Dr. Levin was a member of the Advisory Committee on Immunization Practices (CDC) for 5 years, serving as its Chair for the last 2 years. Dr. Levin has authored >425 original articles and edited 14 books.
University of Oxford, UK
Talk Title: Time for Typhoid
ANDREW J POLLARD, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.
View full bio
His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal and leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and co-leads typhoid vaccine impact studies at these sites. He has supervised 32 PhD students and his publications includes over 400 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE. He received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 and the ESPID Distinguished Award for Education & Communication in 2015. He was elected to the Academy of Medical Sciences in 2016 and is an NIHR Senior Investigator.
Talk Title: Food and water safety: Vaccines for Zoonotic diseases
Dr. Andrew Potter is a graduate of Carleton University (Canada) and the University of Otago (New Zealand) and has worked at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, for the past 33 years serving as a research scientist, Associate Director (Research) and most recently, Director and CEO.
View full bio
His primary research interests are in the areas of the pathogenesis of bacterial respiratory diseases and the development of vaccines for zoonotic diseases. He has previously held an NSERC Senior Industrial Research Chair in the area of vaccine development for food and water safety pathogens. Dr. Potter has mentored more than 49 graduate students and post-doctoral fellows who currently hold positions in industry, academia and government worldwide, and he has contributed to more than 65 patents for human and animal vaccines and therapeutics.
He was also a founding Director and former CEO of the Pan-Provincial Vaccine Enterprise (PREVENT), a National Centre of Excellence in Commercialization and Research funded by the National Centres of Excellence Program of the Federal Government.
Dr. Potter has served on a number of public and private sector committees and Boards, and has been instrumental in transferring VIDO-InterVac technology from the laboratory to the private sector, including five vaccines he developed or co-developed. Dr. Potter has received a number of awards for his work, the most recent being the SHRF Career Achievement Award.
Julius Global Health University Medical Center, The Netherlands
Talk Title: The ADVANCE system for monitoring benefits and risks of vaccines in EU
Miriam Sturkenboom is a pharmacoepidemiologist, currently working at the Julius Global Health group of University Medical Center Utrecht in the Netherlands after having spent 20 years in the department of Medical Informatics at Erasmus MC.
View full bio
She is president of the VACCINE.GRID foundation that promotes global research into the effects of vaccines. She is past president of the International Society for Pharmacoepidemiology. She serves as expert to EMA, FDA, WHO and many other organizations.
Her research interests focus on knowledge discovery from data collected in routine health care to improve evidence on drug and vaccine safety in particular in vulnerable populations (children, pregnancy and elderly). She is coordinator of the European commission funded ADVANCE project aiming to establish a tested system for the monitoring of benefits and risks of vaccines. She pioneered and implemented the data managament and data sharing infrastructures for large collaborative distributed data network studies to allow for European vaccines safety studies during the pandemic VAESCO) and global vaccine and drug studies (SOMNIA, GVS-MCC). In terms of quantitative research outputs: she supervises/d more than 50 PhD students, has more than 380 peer reviewed papers in the area of pharmacovigilance, pharmacoepidemiology and medical informatics and an h-index of 70.
More speakers coming soon.